IN THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of the claims in this application.

1. **(Original)** A method for eliciting an immune response in a subject comprising administering an immunogenically effective amount of a peptide or protein antigen comprising one or more T cell epitope(s) coordinately with a non-viral vector comprising a polynucleotide encoding a T cell co-stimulatory molecule.

2. **(Original)** The method of claim 1, wherein the peptide or protein antigen comprises a T cell epitope of a tumor antigen or viral antigen.

Claims 3 - 5. **(Cancelled)**

6. **(Original)** A method for eliciting an immune response in a subject comprising administering an immunogenically effective amount of a protein antigen comprising at least one T cell epitope coordinately with a non-viral vector comprising a polynucleotide encoding a T cell co-stimulatory molecule.

7. **(Original)** The method of claim 2, wherein the viral antigen is selected from a human immunodeficiency virus (HIV), hepatitis B virus (HBV), hepatitis C virus (HCV), herpes simplex virus (HSV) or human papilloma virus (HPV) antigen.

8. **(Original)** The method of claim 7, wherein the peptide antigen comprises at least nine contiguous amino acids of a HPV antigenic protein.

Claims 9 through 10. **(Cancelled)**

11. **(Original)** The method of claim 1, wherein the co-stimulatory molecule is selected from B7-1, B7-2, B7-3, B7-H, ICAM1, ICAM2, ICAM3, LFA1, LFA2 or LFA3.

12. **(Original)** The method of claim 11, wherein the co-stimulatory molecule is B7-1.

13. **(Original)** The method of claim 1, wherein the peptide antigen and non-viral vector encoding one or more T cell co-stimulatory molecules are administered to the subject simultaneously as a mixture in a pharmaceutically acceptable carrier or diluent.

14. **(Original)** The method of claim 1, wherein the peptide antigen and non-viral vector encoding the T cell co-stimulatory molecule are administered separately to the subject in a sequential vaccination protocol.

15. **(Original)** The method of claim 1, wherein the peptide antigen and non-viral vector encoding the T cell co-stimulatory molecule are administered to proximal target sites selected from the same, or closely-adjacent, intradermal, subcutaneous, mucosal or intratumoral sites.

16. **(Original)** The method of claim 1, wherein the non-viral vector is selected from a RNA or DNA vector.

17. **(Original)** The method of claim 1, wherein the non-viral vector comprises a naked DNA vector having the polynucleotide encoding the co-stimulatory molecule operably linked to regulatory elements necessary for expression of the co-stimulatory molecule in eukaryotic cells.

Claims 18 - 31. **(Cancelled)**